Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Wire to Wire Daily Stock Picking -- Ignore unavailable to you. Want to Upgrade?

To: Katie Kommando who wrote (2184)	7/23/1999 11:41:00 AM
From: The Saint	Respond to of 3514

Can I put BB:CSIN in for Monday I think it will GAB big time NEWS please read Greetings. Today the coldstocksteam presents to you Casino Pirata. (OTC BB:CSIN) at 1.4 $ The float is VERY low: 2.3 million. We are very favorable towards this company as there might be good news to be released very soon. The rumour goes that this news might be about csin getting involved in software development this should give CSIN a huge advantage in the marketplace against its competitors CasinoPirata.com announced that June website hits to www.casinopirata.com have already more than DOUBLED May's hits. The Company's casino is ranked Number One on GOTO.COM INC and in the top ten on the Microsoft search engine. Paul Stringer, President, has publicly stated that he expects first year operating net income to be in excess of $1.50 per share, which would obviously justify share prices to be trading considerably higher than the current price of around $1.00 per share. We have a very strong Buy on CSIN for near term, intermediate term, and long term. If Mr. Stringer is only half right on his earnings estimate and CSIN earns 75 cents and you apply a reasonable PE multiple of 20x, that puts the projected price at $15 in twelve months + or -. THAT'S 15 TIMES THE CURRENT PRICE! First Month Wagering Revenues (MAY 1999) for www.casinopirata.com (OTC BB:CSIN) were $220,000 and the site has received over 200,000 hits so far. CSIN is off to a great start. Paul Stringer, President, has predicted that earnings per share for CSIN's first year of operations would be in excess of $1.50 per share. CSIN is also partners with one of the most complete sports information sites on the Internet We really think csin is going to go up after the news is released short term target: 3 $ long term target :10 $

To: Katie Kommando who wrote (2184)	7/23/1999 11:47:00 AM
From: Jeffrey L. Henken	Respond to of 3514

Wasatch Announces Significant Progress MIDVALE, Utah--(BUSINESS WIRE)--July 23, 1999--Wasatch Pharmaceutical Inc. (OTC BB:WASP) is pleased to announce that significant progress has been made in the last 90 days. Wasatch has spent 15 years conducting world class research in the field of Dermatology. We are ready to take our research to the FDA where we expect to gain fast track approval for a number of indications. We anticipate approval within the next 12 to 18 months. Our products have much broader efficacy with minimal deleterious side effects in comparison to those products currently being marketed. Our products are currently being manufactured by Gordon Laboratories located in Carson, Calif. These products are a combination of prescription drugs and other often used medications. In fact, all these medications have previously received FDA approval but never in the proper combinations that we feel will revolutionize the field of Dermatology. On July 27, 1999, we will be meeting with Dr. Vancampen of the Vancampen Group in order to submit the proper documentation to receive FDA approval to market OTC products for the following indications: 1. Cystic Acne along with lesser grades of acne. With virtually no side effects and a success rate of over 90% in clinical trials, this product will gain broad acceptance in the treatment and prevention of all grades of acne. 2. Folliculitus, a condition involving ingrown hairs along with infection and inflammation. It is especially prevalent in adult males after shaving. 3. Contact Dermatitis, a condition exhibited by skin ulceration, inflammation, rash and itching. 4. Seborrhea, a condition usually associated with the scalp with severe flaking of the skin, sores, rash and itching. 5. Athletes Foot. Wasatch will provide a new approach for the treatment of athletes foot that will result in a permanent eradication of the condition unless exposed to new contaminates resulting from open sores not associated with athletes foot. 6. Cold Sores, as most often exhibited on or in the mouth. The response time in clearing these sores is 2-4 days. 7. Skin Rejuvenation. This OTC product now available only in Wasatch clinics, will provide actual rejuvenation of the skin cells, resulting in beautiful, luxurious skin. In addition to the foregoing OTC products, we have been advised by FDA regulators that we may also make application for use of these products in the burgeoning field of Veterinary medicine. Wasatch has already been approached by major skin care entities for licensing both in the U.S. and foreign markets. These options will be pursued once OTC approvals are received. Further, Wasatch is pleased to announce the former executive at Johnson and Johnson with over 18 years of experience in the skin care division will be announced to the public within the next 90 days. As we await FDA approval, Wasatch Pharmaceuticals expects to begin its expansion phase. The two dermatology clinics which are currently open are expected to be profitable by November of 1999. This is truly an exciting time for Wasatch Pharmaceuticals. We feel we have skin disorder products that will simply dominate market share. NOTE: Any statements released by Wasatch Pharmaceutical Inc. that are not strictly historical are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the company's business prospects and performance. These include economic, competitive, governmental, technological and other factors discussed in the company's filings with the Securities and Exchange Commission. Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709 finance.yahoo.com Wouldn't you know it Katie.. I put it in two days in a row and then when I don't we get good news!!! LOL, Jeff